health news today obesity drugs glp-1 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss GLP-1 medicines entered clinical use

Although there are data in animal models supporting that this is true, particularly in diet-induced obese mice, in which brown adipose tissue activity is regulated [8], there is no convincing evidence that this occurs in humans [6]

From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Dual Role in Prostate Cancer. Cancers, 16*(1538)

She noted that generic semaglutide applications are complex because the originator is a biologic, while the generics are complex synthetic products that must be shown to be pharmaceutically equivalent without compromising safety or efficacy

In this context, GLP-1 receptor agonists are being hailed as "miracle drugs" with demand far exceeding supply in many markets

10.1016/j.cbi.2020.108968 [DOI] [PubMed] [Google Scholar] 52.Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Velez Sanchez P, Wharton S, Wizert A, Kristensen LE, Group SS (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis